Teva: The Next Valeant, Or Worse?

Guest post authored by Ori Hershkovitz, founder and chief investment officer at Nexthera Capital.

Teva’s stock has been under a huge amount of pressure recently, down over 47% since its earnings report on August 3, and down 75% from the highs of over $67 seen only two years ago. The reason for this big dip seems rather obvious – a profit warning that took